Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
Systematic review	3663 people 15 RCTs in this analysis	Mean difference in Hedges-Olkin score for Positive and Negative Syndrome Scale (PANSS) positive improvement with risperidone with first-generation antipsychotic drugs Absolute results not reported	Effect size 0.16 95% CI 0.09 to 0.24 P <0.001	Effect size not calculated	risperidone
Systematic review	3663 people 15 RCTs in this analysis	Mean difference in Hedges-Olkin score for PANSS negative improvement with risperidone with first-generation antipsychotic drugs Absolute results not reported	Effect size 0.20 95% CI 0.13 to 0.28 P <0.001	Effect size not calculated	risperidone
Systematic review	2368 people 9 RCTs in this analysis	No clinically important improvement 12 weeks 789/1809 (44%) with risperidone 292/559 (52%) with first-generation antipsychotic drugs	RR 0.85 95% CI 0.77 to 0.93	Small effect size	risperidone
Systematic review	859 people 2 RCTs in this analysis	No clinically important improvement 26 weeks 191/442 (43%) with risperidone 246/417 (59%) with first-generation antipsychotic drugs	RR 0.73 95% CI 0.65 to 0.83	Small effect size	risperidone
Systematic review	3286 people 28 RCTs in this analysis	Hedges' adjusted g effect size for positive symptoms (PANSS) with risperidone with first-generation antipsychotic drugs Absolute results not reported	Effect size –0.13 95% CI –0.20 to –0.05	Effect size not calculated	risperidone
Systematic review	3455 people 30 RCTs in this analysis	Hedges' adjusted g effect size for negative symptoms (PANSS) with risperidone with first-generation antipsychotic drugs Absolute results not reported	Effect size –0.13 95% CI –0.21 to –0.06	Effect size not calculated	risperidone
RCT	99 people	Response to treatment 8 weeks with risperidone with haloperidol Absolute results reported graphically	Reported as non-significant		Not significant